Sermorelin peptide: benefits, dosage, side effects and how it compares

Growth hormone-releasing hormone was first isolated in 1982, not from the brain but from pancreatic tumours that had caused acromegaly by secreting it. Roger Guillemin’s group and Wylie Vale’s group both published their characterisations that year ^[1][2]. The natural hormone is 44 amino acids long, but a shorter fragment made of its first 29 amino acids still releases growth hormone. Sermorelin is that 1-29 fragment, made synthetically with an amide at the end ^[6].

It is the simplest of the GHRH analogues on this site. Tesamorelin keeps all 44 amino acids and adds a stabilising chemical group; CJC-1295 starts from the same 1-29 sequence as sermorelin but swaps four amino acids and, in its DAC form, adds a group that binds to albumin to extend its life in the blood. Sermorelin has none of these modifications, so it acts briefly.

The licensed product and most research products use sermorelin acetate, the acetate salt of the peptide ^[9]. Sermorelin is a peptide, not a steroid: it is a chain of amino acids that signals the pituitary ^[6]. Clinics that describe “sermorelin peptide therapy” are offering compounded sermorelin, since the Geref brand is no longer made ^[9].

Sermorelin binds the GHRH receptor on the pituitary and triggers a burst of growth hormone (GH) release, which then raises insulin-like growth factor 1 (IGF-1). Because it works through the pituitary rather than replacing GH directly, the release remains subject to the body’s own brakes, principally somatostatin and IGF-1 feedback.

That is the sermorelin mechanism of action in short: it does not act on muscle, fat or skin directly, and any effect on them would come through the extra growth hormone and IGF-1 it produces. It needs a working pituitary to do anything ^[6].

Native GHRH fragments are broken down quickly in the blood, partly by the enzyme DPP-4. That short duration was the practical problem that later analogues were designed to solve; CJC-1295, for example, was engineered for stability against DPP-4 and a longer half-life ^[3]. For sermorelin it means the GH pulse after each injection is short, which is why studies gave it daily or more often.

Sermorelin’s pathway is distinct from the ghrelin-receptor pathway used by ipamorelin and the GHRPs, and early human studies showed that GHRH and a GH-releasing peptide given together produce a greater-than-additive GH response ^[4].

The main clinical programme was in prepubertal children with growth hormone deficiency, which is what the Geref licence was based on. In a multicentre open-label study by the Geref International Study Group, 110 previously untreated children received 30 µg/kg sermorelin under the skin at bedtime for up to a year. Mean height velocity rose from 4.1 cm/year at baseline to 8.0 cm/year at six months and 7.2 cm/year at 12 months, and 74% were judged good responders at six months; no adverse biochemical changes were reported ^[5].

A 1999 drug review concluded that sermorelin was a useful diagnostic test for GH deficiency when given as a single intravenous 1 µg/kg dose alongside conventional tests, and that limited data supported daily treatment in some children. It noted that growth responses were lower than with daily somatropin (recombinant GH) in the studies available, and that its effect on final adult height had not been established ^[6].

That comparison with growth hormone itself is worth spelling out, because sermorelin is often promoted as a “natural” alternative to GH injections. The review found that the recommended sermorelin dose had not been compared directly with somatropin; in the studies that did exist, height gains with sermorelin given by continuous infusion or three divided doses were smaller than with daily somatropin at a similar per-kilogram dose ^[6]. Sermorelin also depends on a pituitary that can still make GH, so it is not a substitute in people whose pituitary cannot respond.

Sermorelin’s first licensed use was diagnostic. A single intravenous dose of 1 µg/kg tests whether the pituitary can release GH. According to the 1999 review, it was rapid and relatively specific, with fewer false-positive results in children without GH deficiency than other stimulation tests, and in adults the combination of sermorelin with arginine was more specific still ^[6]. The review also noted a limitation: because sermorelin acts directly on the pituitary, a normal response cannot rule out GH deficiency caused by a problem in the hypothalamus, so other tests are still needed ^[6].

Much of today’s interest in sermorelin concerns adults with age-related decline in GH, but the evidence here is thin. In a small study in Baltimore, 10 healthy older men took GHRH(1-29), the same sequence as sermorelin, as 0.5 mg or 1 mg injections twice daily for 14 days. The higher dose raised 24-hour GH and IGF-1 to levels no longer different from those of young men, without changing glucose or blood pressure ^[7].

A follow-up study gave 11 healthy men aged 64 to 76 a single 2 mg injection each night for six weeks. Night-time GH release increased, but IGF-1, body composition, weight and lipids did not change; two of six strength measures and one endurance test improved. The authors concluded that single nightly doses were less effective than multiple daily doses ^[8]. Taken together with the earlier twice-daily study, in which IGF-1 did rise ^[7], this is consistent with sermorelin’s short action: one daily pulse may not be enough to raise IGF-1 in older adults. There are no large or long-term randomised trials of sermorelin for ageing, body composition or athletic performance.

The sermorelin benefits that are backed by trials are its original uses: faster growth in children with growth hormone deficiency ^[5] and a diagnostic test of pituitary function ^[6]. In adults, the studies measured hormones rather than outcomes. Twice-daily injections restored growth hormone and IGF-1 in older men to young-adult levels over two weeks ^[7], but a six-week nightly regimen changed neither IGF-1 nor body composition ^[8].

So the evidence for sermorelin weight loss or muscle growth is weak. The six-week study found no change in lean mass, fat or weight, with small gains in two of six strength measures ^[8]. No trial has tested sermorelin for fat loss, bodybuilding or appearance in healthy adults. The adult studies cited here were all in men, so claims about sermorelin benefits for females rest on no direct evidence.

In children with growth hormone deficiency, the one setting with clear results, height velocity roughly doubled by six months ^[5]. In older men, growth hormone and IGF-1 rose within 14 days of twice-daily dosing ^[7]. Beyond those findings there are no trial data on how long sermorelin takes to work for any adult goal.

Sermorelin before and after photos, including those focused on the face, and Reddit threads are uncontrolled. They rarely say what product or dose was used, and they often come from clinics that sell the treatment. No study has measured sermorelin’s effect on facial appearance, skin or hair. Whether sermorelin is worth it for any adult use cannot be judged from published trials, because the trials that would answer it have not been done.

Sermorelin has more human data than most research peptides because it was a licensed drug: paediatric efficacy studies ^[5], a diagnostic-test literature ^[6], and a handful of short physiological studies in older men ^[7][8]. What it lacks is modern, adequately sized, placebo-controlled trials in adults. Claims about anti-ageing, fat loss or muscle gain in adults rest mostly on extrapolation from its effect on GH and IGF-1 rather than on outcome trials.

The two are often compared because both stimulate GH through the GHRH receptor. The differences are in structure and in the evidence. Sermorelin is the unmodified 1-29 fragment, short-acting, and its trial evidence is mainly paediatric plus small adult studies ^[5][7][8]. Tesamorelin is the full 44-amino-acid hormone with a stabilising hexenoyl group, and it has phase 3 randomised trials showing reduced visceral fat in people with HIV and a current US licence for that use ^[14]. Its Canadian listing has been cancelled ^[15]. They have never been compared head to head, so there is no direct evidence that either is more effective for any outcome. Our Tesamorelin vs sermorelin comparison sets the two side by side.

The pharmacology differs only in degree. Unmodified GHRH(1-29) disappears from the blood with a half-time of about 4 minutes when infused into a vein ^[11]. The tesamorelin label gives an elimination half-life of 8 to 11 minutes, depending on the formulation ^[14]. Both produce growth hormone pulses that outlast the drug: after an intravenous dose of GHRH(1-29), growth hormone stayed raised for about three hours ^[12].

The bigger difference is regulatory. Tesamorelin is a current US prescription medicine with a defined use and a label listing its side effects and warnings ^[14]. Sermorelin has had no approved product since 2009, so what is sold today is compounded or research material ^[9]. For someone choosing between sermorelin or tesamorelin, the evidence does not show one works better, but it does show that only tesamorelin has adult phase 3 data. Taking tesamorelin and sermorelin together would stimulate the same receptor twice, and no study has tested the combination.

Ipamorelin acts on a different receptor, the ghrelin receptor, and was developed as a selective growth hormone secretagogue that, in animal studies, did not raise ACTH or cortisol ^[16]. Its half-life in healthy volunteers was about 2 hours ^[17], much longer than sermorelin’s. It was never approved; a phase 2 trial in 117 patients after bowel surgery found no significant benefit ^[18]. Sermorelin, at least, was once a licensed medicine. Our Ipamorelin vs sermorelin comparison sets the two side by side.

Because the two act through separate pathways, a GHRH analogue and a ghrelin mimetic given together release more growth hormone than either alone ^[4]. That is the reasoning behind sermorelin and ipamorelin blends, but the synergy was shown with a different GHRP, and no study has tested sermorelin with ipamorelin for any outcome.

CJC-1295 starts from the same 1-29 sequence but was engineered to last. In healthy adults its half-life was 5.8 to 8.1 days, and a single injection raised growth hormone and IGF-1 for a week or more ^[19]. Sermorelin acts for minutes. Neither is an approved medicine today, and they have not been compared in a trial, nor has sermorelin been compared with CJC-1295 and ipamorelin used together.

Growth hormone itself (somatropin) acts directly on tissues, while sermorelin asks the pituitary to release more of the body’s own. Somatropin is an approved medicine and, in the UK, a Class C controlled drug; sermorelin is not named in that schedule ^[20]. In children, growth responses were smaller with sermorelin than with daily somatropin ^[6].

MK-677 (ibutamoren) is a pill that acts on the ghrelin receptor rather than the GHRH receptor. In a trial in 65 healthy older adults, 25 mg daily for up to two years raised fat-free mass by about 1.1 kg compared with placebo, but also raised fasting glucose ^[21]. It has never been approved, and no study has compared it with sermorelin.

Sermorelin is not a form of testosterone replacement therapy. It contains no testosterone, and the adult studies reported its effects on growth hormone and IGF-1, not on testosterone ^[7][8]. We found no trial showing that sermorelin increases testosterone, so sermorelin vs TRT is a comparison between drugs that act on different hormones.

Sermorelin is sometimes sold or prescribed alongside other peptides. GHK-Cu is a copper peptide used mainly in skin products; tirzepatide is an approved weight-loss and diabetes medicine; retatrutide is an experimental drug that is not approved in the US ^[22]. No study has tested sermorelin with any of them, so nothing is known about taking sermorelin and tirzepatide together or about any of these combinations.

Studies used quite different regimens depending on the purpose. As a diagnostic test, a single intravenous dose of 1 µg/kg was used ^[6]. For treating children with GH deficiency, the licensed regimen studied was 30 µg/kg under the skin once daily at bedtime ^[5][6]. In older men, studies used 0.5 mg or 1 mg twice daily for 14 days ^[7] and 2 mg once nightly for six weeks ^[8].

These are the doses reported in the cited studies, not recommendations. For converting between milligrams, micrograms and injection volumes in a laboratory setting, see our peptide calculator.

Searches about when to take sermorelin often ask about the morning. The paediatric trial and the six-week adult study gave it at bedtime ^[5][8], and the 14-day study gave it twice daily ^[7]; no study compared morning with evening dosing. Sermorelin dosage charts for bodybuilding, muscle growth, men or women, and set cycle lengths, do not come from these trials. Questions about millilitres and units are arithmetic: a 9 mg vial mixed with 3 mL of diluent gives 3 mg per mL, so each unit on a U-100 insulin syringe holds 0.03 mg (30 µg).

Geref was an injection: under the skin for treatment and into a vein for the diagnostic test ^[5][6]. Even by injection, much of the peptide is lost. In rats, the amount reaching the blood after an injection under the skin was only 4% of that after an intravenous dose ^[13].

The only other route tested in people is intranasal, the idea behind a sermorelin nasal spray. In 30 healthy men, only 3 to 5% of an intranasal dose was absorbed, and about 50 times the intravenous dose was needed for a similar growth hormone response ^[12]. When children with growth hormone deficiency used an intranasal form three times a day for six months, the response faded, three developed antibodies, most had sneezing, a runny nose or burning, and height velocity did not increase; the authors judged it unsuitable in that form ^[23].

We found no published study of sermorelin tablets, pills, oral drops or sublingual tablets. So there is no evidence on sermorelin oral vs injection or sermorelin pills vs injections, and no data showing that a swallowed or dissolved form reaches the blood. On where to inject sermorelin, the sources we checked say only that the paediatric doses were given under the skin at bedtime ^[5]; they do not name injection sites. Injection-site pain was among the common complaints ^[6].

Sermorelin’s half-life is a matter of minutes: about 4 minutes after intravenous infusion in men ^[11], and about 10 minutes for the elimination phase in rats ^[13]. It therefore leaves the body within an hour or so, although the growth hormone pulse it causes lasts a few hours ^[12].

Whether sermorelin needs to be refrigerated has no evidence-based answer for research products, because no stability studies have been published for them. General guidance for freeze-dried and mixed peptides is in our storage guide.

In the clinical literature sermorelin was generally well tolerated. The most commonly reported adverse events were transient facial flushing and pain at the injection site ^[6]. Flushing is a recognised effect of GHRH itself: in an early study of the full-length hormone, 16 of 18 men had brief flushing after an intravenous dose ^[4]. The paediatric trial reported no adverse changes in routine blood tests, fasting glucose or IGF-1 ^[5].

Because it raises GH and IGF-1, the theoretical concerns that apply to other GH-axis drugs (fluid retention, effects on glucose, and a hypothetical effect on existing tumours) apply here too, but the adult studies were too small and short to measure them. Safety data from a licensed pharmaceutical product also do not transfer to unlicensed research-grade material of unknown purity.

Sermorelin long-term side effects in adults have not been studied, because no adult trial lasted longer than a few weeks. On cancer, there is no evidence that sermorelin causes it, but because it raises growth hormone and IGF-1, the same caution about existing tumours that appears on the tesamorelin label applies in principle ^[14]. We found no study linking sermorelin to hair loss, and none measuring it. The sermorelin side effects reported in men in the adult studies were few, but those studies were small and short ^[7][8].

Quality is a separate risk. In 2016 a US compounding pharmacy recalled all lots of its sermorelin and HCG because it could not assure their sterility, and the FDA later cited the firm in a warning letter ^[24]. Whether sermorelin is safe in any particular form therefore depends partly on who made it, which is why independent testing matters.

No study has followed adults after stopping sermorelin, so there is no trial evidence about what happens when you stop taking sermorelin.

In the US, sermorelin acetate was approved as Geref in two forms: a 0.05 mg ampoule in December 1990 for testing the pituitary’s ability to secrete GH, and 0.5 mg and 1.0 mg vials in September 1997 for treating idiopathic GH deficiency in children with growth failure. The holder, EMD Serono, discontinued both in 2008 and the FDA withdrew approval with effect from 18 June 2009. In March 2013 the FDA published a determination that Geref was not withdrawn from sale for reasons of safety or effectiveness, which in principle allows generic applications ^[9].

It is sometimes said that sermorelin was “withdrawn because it didn’t work” or “banned by the FDA”; neither is accurate according to that determination. Equally, there is currently no FDA-approved sermorelin product on the market. We could not confirm a current licence in the UK, Canada, Australia or New Zealand. See our legal status overview, including the US page.

Questions about the sermorelin FDA 503A status come from US compounding rules. A pharmacy compounding under section 503A may use a bulk substance only if it has a USP or National Formulary monograph, is a component of an FDA-approved drug, or appears on the FDA’s 503A bulks list ^[25]. That list currently contains no peptides ^[26], and sermorelin does not appear on the FDA’s list of substances that may present significant safety risks ^[27]. The FDA has published no sermorelin-specific statement on its compounding status that we could find.

New Zealand’s Medsafe classifies sermorelin as a prescription medicine ^[28]. Australia’s Poisons Standard places growth hormone-releasing hormones in Schedule 4 with Appendix D controls ^[29]; see our Australian legal status page. In the UK it has no marketing authorisation, and our UK legal status page explains the rules on unlicensed medicines.

Sermorelin is named on the WADA Prohibited List under S2 (GHRH and its analogues) and is banned at all times, so in sport it is treated as a performance-enhancing drug ^[10].

Research-grade sermorelin is sold as a freeze-dried powder. There are no published stability studies for these products, so storage follows general practice for lyophilised peptides; see our guides to storing peptides and bacteriostatic water.

Sermorelin is widely stocked and relatively cheap per milligram. Compare prices, check any certificate of analysis with our guide on how to read a COA, and prefer third-party tested suppliers.

Sermorelin cost varies with the route. Clinic programmes bundle a prescription, consultation and compounded vials, while research listings sell vials alone. Our UK sermorelin prices and Australian prices track research listings, and how peptide prices work explains per-milligram comparisons. Sellers that promise pharmacy-grade sermorelin without a prescription are a warning sign; see how to spot a fake peptide supplier.